Accessibility Menu
Ampio Pharmaceuticals Stock Quote

Ampio Pharmaceuticals (OTC: AMPE)

$0.00
(14.8%)
+0.00
Price as of October 20, 2025, 3:35 p.m. ET

KEY DATA POINTS

Current Price
$0
Daily Change
(14.8%) +$0.00
Day's Range
$0 - $0
Previous Close
$0
Open
$0
Beta
0
Volume
21
Average Volume
867
Market Cap
3.5K
Market Cap / Employee
$0.00M
52wk Range
$0 - $0.16
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
$0
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Ampio Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
AMPE+40.91%N/AN/A-100%
S&P+15.06%+95.03%+14.29%+488%

Ampio Pharmaceuticals Company Info

Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease. The company was founded by David Bar-Or in December 2008 and is headquartered in Englewood, CO.

News & Analysis

Financial Health

General

Q4 2023YOY Change
Revenue$0.00M0.0%
Gross Profit$0.00M0.0%
Market Cap$1.71M0.0%
Market Cap / Employee$0.28M0.0%
Employees60.0%
Net Income-$2.05M0.0%
EBITDA-$2.22M0.0%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q4 2023YOY Change
Net Cash$4.09M0.0%
Inventory00.0%

Liabilities

Q4 2023YOY Change
Long Term Debt$0.00M0.0%
Short Term Debt$0.27M0.0%

Ratios

Q4 2023YOY Change
Return On Assets-89.34%0.0%
Return On Invested Capital37.63%0.0%

Cash Flow

Q4 2023YOY Change
Free Cash Flow-$2.31M0.0%
Operating Free Cash Flow-$2.31M0.0%

Valuation

MetricQ4 2023YoY Change
Price to Book0.31-
Price to Tangible Book Value0.31-
Enterprise Value to EBITDA0.95-
Return on Equity-114.0%-
Total Debt$0.27M-

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.